ストックスクリーナーアプリを入手
0.00
100.00%
-0.10
前日終値:
$0.10
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
$30.00M
当期純損益:
$-38.17M
株価収益率:
0.00
EPS:
-1.3
ネットキャッシュフロー:
$-35.49M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-69.27%
1年 パフォーマンス:
-85.40%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
TBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.00 | 0 | 30.00M | -38.17M | -35.49M | -1.30 |
|
ABT
Abbott Laboratories
|
131.30 | 229.51B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.34 | 155.75B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.73 | 149.44B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.05 | 117.93B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.25 | 47.47B | 5.69B | 1.41B | 577.90M | 6.95 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-03-18 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-03-18 | ダウングレード | Truist | Buy → Hold |
| 2020-10-05 | 開始されました | Goldman | Buy |
| 2020-07-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-06 | 開始されました | William Blair | Outperform |
| 2020-06-26 | 開始されました | SunTrust | Buy |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-06-18 | 開始されました | ROTH Capital | Buy |
| 2018-12-24 | 開始されました | H.C. Wainwright | Buy |
| 2018-07-23 | 開始されました | Citigroup | Buy |
| 2018-07-23 | 開始されました | Evercore ISI | Outperform |
| 2018-07-23 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Telesis Bio Inc (TBIO) 最新ニュース
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight - GlobeNewswire
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities - Yahoo Finance
Regeneron partners with Telesis Bio for swift on-site gene synthesis - World Pharmaceutical Frontiers
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency - Insider Monkey
Regeneron (REGN) Adopts Telesis Bio's Gene Synthesis Platform | - GuruFocus
Regeneron Pharmaceuticals (NasdaqGS:REGN) Adopts Innovative Technology for Faster Drug Discovery - Yahoo Finance
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
What is going on with the stock tbio - AInvest
Telesis Bio (NASDAQ:TBIO) Stock Price Up 28.9% – Here’s Why - American Banking and Market News
Telesis Bio (NASDAQ:TBIO) Trading Up 28.9% – Still a Buy? - Defense World
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
TELESIS BIO INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
FT ranking: The Americas’ Fastest-Growing Companies 2025 - Financial Times
Telesis Bio (NASDAQ:TBIO) Trading Down 23.1% – Here’s Why - Defense World
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - StockTitan
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Telesis Bio (NASDAQ:TBIO) Trading 27.3% Higher – Should You Buy? - Defense World
Financial Contrast: Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRE) - Defense World
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
One new option listing and ten option delistings on October 21st - TipRanks
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Telesis Bio Stock Skyrockets after Beckman Coulter Partnership - timothysykes.com
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Codex DNA stock plunges to 52-week low of $1.65 - Investing.com
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market | TBIO Stock News - Stock Titan
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Enzymatic DNA Synthesis Market Size | Industry Report 2033 - Grand View Research
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Yahoo Finance
DNA Synthesis Market Size, Share | Growth Report [2025-2032] - Fortune Business Insights
Telesis Bio Reports First Quarter 2024 Financial Results - Yahoo Finance
Telesis Bio Announces Reverse Stock Split - Yahoo Finance
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Koreabizwire
Press Release Service: Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering TechnologiesResearchAndMarkets.com - CRISPR Medicine News
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023, Business Wires News - AsiaOne
Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 - openPR.com
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio to Present at Jefferies Healthcare Conference 2023 - Koreabizwire
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin LLP
Telesis Bio Inc (TBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
0.49%
大文字化:
|
ボリューム (24 時間):